AminologicsLtd (A074430) 주식 개요아미노로직스는 특수 아미노산 공급업체로, 한국의 제약 및 정밀 화학 산업을 위한 다양한 아미노산 기반 원료를 개발합니다. 자세히 보기A074430 펀더멘털 분석스노우플레이크 점수가치 평가0/6미래 성장0/6과거 실적2/6재무 건전성4/6배당0/6강점올해부터 흑자전환위험 분석지난 5년간 매년 수익이 20.4% 감소했습니다.의미 있는 시가총액이 없습니다(₩117B)모든 위험 점검 보기A074430 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value₩Current Price₩1.33k74.7% 고평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-7b27b2016201920222025202620282031Revenue ₩18.9bEarnings ₩3.0bAdvancedSet Fair ValueView all narrativesFeatured narrative•Materials opportunityUpside Gold3 months ago author updated this narrativeSTFair Value from stuart_robertsCA$5.0768.0% 저평가 내재 할인율An Undervalued 3.3Moz Gold Project in CanadaKey takeaways Upside Gold is developing the Kena Gold Project, near the town of Nelson in the Kootenays region of southern British Columbia. Kena hosts a historical gold resource of 3.33 million ounces (561,000 ounces Indicated and 2.77 million ounces Inferred) across a 10,200-hectare land package.Read full narrative15.3kusers have viewed this narrative42users have liked this narrative1users have commented on this narrative287users have followed this narrativeRead narrativeAminologics Co.,Ltd. 경쟁사TapexSymbol: KOSE:A055490Market cap: ₩96.3bMSCSymbol: KOSDAQ:A009780Market cap: ₩126.0bDongnam ChemicalSymbol: KOSE:A023450Market cap: ₩114.5bDaebongls.Co.LtdSymbol: KOSDAQ:A078140Market cap: ₩118.6b가격 이력 및 성과AminologicsLtd 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가₩1,327.0052주 최고가₩1,940.0052주 최저가₩855.00베타0.691개월 변동-7.46%3개월 변동-15.80%1년 변동38.81%3년 변동-24.47%5년 변동-60.45%IPO 이후 변동-44.48%최근 뉴스 및 업데이트New Risk • Apr 03New major risk - Revenue and earnings growthEarnings have declined by 20% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 20% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩122.7b market cap, or US$81.3m).Valuation Update With 7 Day Price Move • Mar 30Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩1,555, the stock trades at a trailing P/E ratio of 70x. Average trailing P/E is 14x in the Chemicals industry in South Korea. Total loss to shareholders of 18% over the past three years.공지 • Mar 13Aminologics Co.,Ltd., Annual General Meeting, Mar 31, 2026Aminologics Co.,Ltd., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: dasan hall, 114, taebong-ro, seocho-gu, seoul South KoreaValuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to ₩1,299, the stock trades at a trailing P/E ratio of 58.5x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total loss to shareholders of 31% over the past three years.Valuation Update With 7 Day Price Move • Jan 30Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩1,532, the stock trades at a trailing P/E ratio of 68.9x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total loss to shareholders of 24% over the past three years.분석 기사 • Jan 21AminologicsLtd (KOSDAQ:074430) Shareholders Will Want The ROCE Trajectory To ContinueThere are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...더 많은 업데이트 보기Recent updatesNew Risk • Apr 03New major risk - Revenue and earnings growthEarnings have declined by 20% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 20% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩122.7b market cap, or US$81.3m).Valuation Update With 7 Day Price Move • Mar 30Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩1,555, the stock trades at a trailing P/E ratio of 70x. Average trailing P/E is 14x in the Chemicals industry in South Korea. Total loss to shareholders of 18% over the past three years.공지 • Mar 13Aminologics Co.,Ltd., Annual General Meeting, Mar 31, 2026Aminologics Co.,Ltd., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: dasan hall, 114, taebong-ro, seocho-gu, seoul South KoreaValuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to ₩1,299, the stock trades at a trailing P/E ratio of 58.5x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total loss to shareholders of 31% over the past three years.Valuation Update With 7 Day Price Move • Jan 30Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩1,532, the stock trades at a trailing P/E ratio of 68.9x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total loss to shareholders of 24% over the past three years.분석 기사 • Jan 21AminologicsLtd (KOSDAQ:074430) Shareholders Will Want The ROCE Trajectory To ContinueThere are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...분석 기사 • Dec 30AminologicsLtd (KOSDAQ:074430) Has A Rock Solid Balance SheetWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...분석 기사 • Dec 30Subdued Growth No Barrier To Aminologics Co.,Ltd. (KOSDAQ:074430) With Shares Advancing 27%Aminologics Co.,Ltd. ( KOSDAQ:074430 ) shares have had a really impressive month, gaining 27% after a shaky period...New Risk • Dec 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.7% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (₩104.9b market cap, or US$72.7m).Valuation Update With 7 Day Price Move • Dec 30Investor sentiment improves as stock rises 30%After last week's 30% share price gain to ₩1,194, the stock trades at a trailing P/E ratio of 53.7x. Average trailing P/E is 11x in the Chemicals industry in South Korea. Total loss to shareholders of 33% over the past three years.분석 기사 • Nov 21AminologicsLtd's (KOSDAQ:074430) Earnings Seem To Be PromisingThe market seemed underwhelmed by last week's earnings announcement from Aminologics Co.,Ltd. ( KOSDAQ:074430 ) despite...Reported Earnings • Nov 20Third quarter 2025 earnings released: EPS: ₩15.00 (vs ₩17.00 loss in 3Q 2024)Third quarter 2025 results: EPS: ₩15.00 (up from ₩17.00 loss in 3Q 2024). Revenue: ₩6.01b (up 151% from 3Q 2024). Net income: ₩1.36b (up ₩2.89b from 3Q 2024). Profit margin: 23% (up from net loss in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.분석 기사 • Nov 12Risks To Shareholder Returns Are Elevated At These Prices For Aminologics Co.,Ltd. (KOSDAQ:074430)When close to half the companies in the Chemicals industry in Korea have price-to-sales ratios (or "P/S") below 0.7x...New Risk • Aug 30New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). Minor Risk Market cap is less than US$100m (₩90.7b market cap, or US$65.4m).New Risk • Apr 01New major risk - Revenue and earnings growthEarnings have declined by 13% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 13% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩78.1b market cap, or US$53.2m).공지 • Mar 01Aminologics Co.,Ltd., Annual General Meeting, Mar 31, 2025Aminologics Co.,Ltd., Annual General Meeting, Mar 31, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 114, taebong-ro, seocho-gu, seoul South Korea분석 기사 • Nov 15There May Be Underlying Issues With The Quality Of AminologicsLtd's (KOSDAQ:074430) EarningsDespite announcing strong earnings, Aminologics Co.,Ltd.'s ( KOSDAQ:074430 ) stock was sluggish. We think that the...Reported Earnings • Nov 12Third quarter 2024 earnings released: ₩17.00 loss per share (vs ₩6.00 loss in 3Q 2023)Third quarter 2024 results: ₩17.00 loss per share (further deteriorated from ₩6.00 loss in 3Q 2023). Revenue: ₩2.39b (down 43% from 3Q 2023). Net loss: ₩1.53b (loss widened 177% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has only fallen by 24% per year, which means it has not declined as severely as earnings.New Risk • Sep 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩102.1b market cap, or US$77.6m).분석 기사 • Aug 13AminologicsLtd (KOSDAQ:074430) May Have Issues Allocating Its CapitalTo avoid investing in a business that's in decline, there's a few financial metrics that can provide early indications...Valuation Update With 7 Day Price Move • Aug 05Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩1,157, the stock trades at a trailing P/E ratio of 39.5x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total loss to shareholders of 61% over the past three years.분석 기사 • Mar 27AminologicsLtd's (KOSDAQ:074430) Shareholders May Want To Dig Deeper Than Statutory ProfitFollowing the solid earnings report from Aminologics Co.,Ltd. ( KOSDAQ:074430 ), the market responded by bidding up the...Reported Earnings • Mar 26Full year 2023 earnings released: EPS: ₩28.00 (vs ₩83.00 loss in FY 2022)Full year 2023 results: EPS: ₩28.00 (up from ₩83.00 loss in FY 2022). Revenue: ₩20.9b (down 24% from FY 2022). Net income: ₩2.44b (up ₩9.72b from FY 2022). Profit margin: 12% (up from net loss in FY 2022). The move to profitability was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 63 percentage points per year, which is a significant difference in performance.분석 기사 • Mar 01Some Investors May Be Worried About AminologicsLtd's (KOSDAQ:074430) Returns On CapitalWhen it comes to investing, there are some useful financial metrics that can warn us when a business is potentially in...New Risk • Jul 26New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩123.4b (US$96.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 17% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩123.4b market cap, or US$96.4m).Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Valuation Update With 7 Day Price Move • Jun 23Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to ₩2,465, the stock trades at a trailing P/E ratio of 28.1x. Average trailing P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 14% over the past three years.Valuation Update With 7 Day Price Move • Jun 09Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₩2,845, the stock trades at a trailing P/E ratio of 32.4x. Average trailing P/E is 15x in the Chemicals industry in South Korea. Total returns to shareholders of 35% over the past three years.Valuation Update With 7 Day Price Move • May 18Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₩2,645, the stock trades at a trailing P/E ratio of 43.3x. Average trailing P/E is 15x in the Chemicals industry in South Korea. Total returns to shareholders of 31% over the past three years.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Valuation Update With 7 Day Price Move • Apr 19Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩2,310, the stock trades at a trailing P/E ratio of 37.9x. Average trailing P/E is 16x in the Chemicals industry in South Korea. Total returns to shareholders of 5.0% over the past three years.Reported Earnings • Nov 13Third quarter 2021 earnings released: EPS ₩11.00 (vs ₩8.00 in 3Q 2020)The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2021 results: Revenue: ₩4.41b (down 15% from 3Q 2020). Net income: ₩961.5m (up 35% from 3Q 2020). Profit margin: 22% (up from 14% in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • Oct 06Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩2,345, the stock trades at a trailing P/E ratio of 29.1x. Average trailing P/E is 19x in the Chemicals industry in South Korea. Total returns to shareholders of 8.1% over the past three years.Reported Earnings • May 19First quarter 2021 earnings released: EPS ₩10.00 (vs ₩5.00 loss in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: ₩4.41b (up 8.5% from 1Q 2020). Net income: ₩869.4m (up ₩1.30b from 1Q 2020). Profit margin: 20% (up from net loss in 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has increased by 19% per year, which means it is well ahead of earnings.분석 기사 • May 05Returns At AminologicsLtd (KOSDAQ:074430) Are On The Way UpFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...분석 기사 • Mar 19Should Weakness in Aminologics Co.,Ltd.'s (KOSDAQ:074430) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?With its stock down 7.9% over the past three months, it is easy to disregard AminologicsLtd (KOSDAQ:074430). But if you...Reported Earnings • Mar 19Full year 2020 earnings released: EPS ₩24.00 (vs ₩14.00 loss in FY 2019)The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2020 results: Revenue: ₩17.7b (down 7.0% from FY 2019). Net income: ₩2.14b (up ₩3.34b from FY 2019). Profit margin: 12% (up from net loss in FY 2019). Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings.Is New 90 Day High Low • Mar 09New 90-day low: ₩2,400The company is down 19% from its price of ₩2,970 on 09 December 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 12% over the same period.분석 기사 • Feb 04If You Had Bought AminologicsLtd (KOSDAQ:074430) Stock Five Years Ago, You Could Pocket A 137% Gain TodayWhen you buy a stock there is always a possibility that it could drop 100%. But when you pick a company that is really...Is New 90 Day High Low • Jan 06New 90-day high: ₩3,405The company is up 49% from its price of ₩2,285 on 08 October 2020. The South Korean market is up 24% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 25% over the same period.Is New 90 Day High Low • Dec 04New 90-day high: ₩2,740The company is up 13% from its price of ₩2,415 on 04 September 2020. The South Korean market is also up 13% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Chemicals industry, which is up 12% over the same period.Is New 90 Day High Low • Oct 18New 90-day low: ₩2,030The company is down 2.0% from its price of ₩2,080 on 20 July 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 25% over the same period.주주 수익률A074430KR ChemicalsKR 시장7D-4.3%0.1%12.5%1Y38.8%76.7%176.4%전체 주주 수익률 보기수익률 대 산업: A074430은 지난 1년 동안 76.7%의 수익을 기록한 KR Chemicals 산업보다 저조한 성과를 냈습니다.수익률 대 시장: A074430은 지난 1년 동안 176.4%를 기록한 KR 시장보다 저조한 성과를 냈습니다.주가 변동성Is A074430's price volatile compared to industry and market?A074430 volatilityA074430 Average Weekly Movement9.4%Chemicals Industry Average Movement9.4%Market Average Movement9.1%10% most volatile stocks in KR Market16.2%10% least volatile stocks in KR Market4.7%안정적인 주가: A074430는 지난 3개월 동안 KR 시장에 비해 주가 변동성이 크지 않았습니다.시간에 따른 변동성: A074430의 주간 변동성(9%)은 지난 1년 동안 안정적이었습니다.회사 소개설립직원 수CEO웹사이트199740J. S. Ohwww.aminologics.co.kr아미노로직스는 특수 아미노산 공급업체로 한국의 제약 및 정밀화학 산업을 위한 다양한 아미노산 기반 원료를 개발합니다. 아미노로직스의 제품에는 Fmoc, Boc 및 CBZ 아미노산이 포함됩니다. 또한 지질과 아미노산 유도체도 제공합니다.더 보기Aminologics Co.,Ltd. 기초 지표 요약AminologicsLtd의 순이익과 매출은 시가총액과 어떻게 비교됩니까?A074430 기초 통계시가총액₩116.55b순이익 (TTM)₩3.52b매출 (TTM)₩22.02b33.1x주가수익비율(P/E)5.3x주가매출비율(P/S)A074430는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표A074430 손익계산서 (TTM)매출₩22.02b매출원가₩12.19b총이익₩9.83b기타 비용₩6.31b순이익₩3.52b최근 보고된 실적Dec 31, 2025다음 실적 발표일해당 없음주당순이익(EPS)40.10총이익률44.65%순이익률15.99%부채/자본 비율27.6%A074430의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/09 07:25종가2026/05/08 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Aminologics Co.,Ltd.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Featured narrative•Materials opportunityUpside Gold3 months ago author updated this narrativeSTFair Value from stuart_robertsCA$5.0768.0% 저평가 내재 할인율An Undervalued 3.3Moz Gold Project in CanadaKey takeaways Upside Gold is developing the Kena Gold Project, near the town of Nelson in the Kootenays region of southern British Columbia. Kena hosts a historical gold resource of 3.33 million ounces (561,000 ounces Indicated and 2.77 million ounces Inferred) across a 10,200-hectare land package.Read full narrative15.3kusers have viewed this narrative42users have liked this narrative1users have commented on this narrative287users have followed this narrativeRead narrative
New Risk • Apr 03New major risk - Revenue and earnings growthEarnings have declined by 20% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 20% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩122.7b market cap, or US$81.3m).
Valuation Update With 7 Day Price Move • Mar 30Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩1,555, the stock trades at a trailing P/E ratio of 70x. Average trailing P/E is 14x in the Chemicals industry in South Korea. Total loss to shareholders of 18% over the past three years.
공지 • Mar 13Aminologics Co.,Ltd., Annual General Meeting, Mar 31, 2026Aminologics Co.,Ltd., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: dasan hall, 114, taebong-ro, seocho-gu, seoul South Korea
Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to ₩1,299, the stock trades at a trailing P/E ratio of 58.5x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total loss to shareholders of 31% over the past three years.
Valuation Update With 7 Day Price Move • Jan 30Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩1,532, the stock trades at a trailing P/E ratio of 68.9x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total loss to shareholders of 24% over the past three years.
분석 기사 • Jan 21AminologicsLtd (KOSDAQ:074430) Shareholders Will Want The ROCE Trajectory To ContinueThere are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...
New Risk • Apr 03New major risk - Revenue and earnings growthEarnings have declined by 20% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 20% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩122.7b market cap, or US$81.3m).
Valuation Update With 7 Day Price Move • Mar 30Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩1,555, the stock trades at a trailing P/E ratio of 70x. Average trailing P/E is 14x in the Chemicals industry in South Korea. Total loss to shareholders of 18% over the past three years.
공지 • Mar 13Aminologics Co.,Ltd., Annual General Meeting, Mar 31, 2026Aminologics Co.,Ltd., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: dasan hall, 114, taebong-ro, seocho-gu, seoul South Korea
Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to ₩1,299, the stock trades at a trailing P/E ratio of 58.5x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total loss to shareholders of 31% over the past three years.
Valuation Update With 7 Day Price Move • Jan 30Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩1,532, the stock trades at a trailing P/E ratio of 68.9x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total loss to shareholders of 24% over the past three years.
분석 기사 • Jan 21AminologicsLtd (KOSDAQ:074430) Shareholders Will Want The ROCE Trajectory To ContinueThere are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...
분석 기사 • Dec 30AminologicsLtd (KOSDAQ:074430) Has A Rock Solid Balance SheetWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
분석 기사 • Dec 30Subdued Growth No Barrier To Aminologics Co.,Ltd. (KOSDAQ:074430) With Shares Advancing 27%Aminologics Co.,Ltd. ( KOSDAQ:074430 ) shares have had a really impressive month, gaining 27% after a shaky period...
New Risk • Dec 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.7% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (₩104.9b market cap, or US$72.7m).
Valuation Update With 7 Day Price Move • Dec 30Investor sentiment improves as stock rises 30%After last week's 30% share price gain to ₩1,194, the stock trades at a trailing P/E ratio of 53.7x. Average trailing P/E is 11x in the Chemicals industry in South Korea. Total loss to shareholders of 33% over the past three years.
분석 기사 • Nov 21AminologicsLtd's (KOSDAQ:074430) Earnings Seem To Be PromisingThe market seemed underwhelmed by last week's earnings announcement from Aminologics Co.,Ltd. ( KOSDAQ:074430 ) despite...
Reported Earnings • Nov 20Third quarter 2025 earnings released: EPS: ₩15.00 (vs ₩17.00 loss in 3Q 2024)Third quarter 2025 results: EPS: ₩15.00 (up from ₩17.00 loss in 3Q 2024). Revenue: ₩6.01b (up 151% from 3Q 2024). Net income: ₩1.36b (up ₩2.89b from 3Q 2024). Profit margin: 23% (up from net loss in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.
분석 기사 • Nov 12Risks To Shareholder Returns Are Elevated At These Prices For Aminologics Co.,Ltd. (KOSDAQ:074430)When close to half the companies in the Chemicals industry in Korea have price-to-sales ratios (or "P/S") below 0.7x...
New Risk • Aug 30New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). Minor Risk Market cap is less than US$100m (₩90.7b market cap, or US$65.4m).
New Risk • Apr 01New major risk - Revenue and earnings growthEarnings have declined by 13% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 13% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩78.1b market cap, or US$53.2m).
공지 • Mar 01Aminologics Co.,Ltd., Annual General Meeting, Mar 31, 2025Aminologics Co.,Ltd., Annual General Meeting, Mar 31, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 114, taebong-ro, seocho-gu, seoul South Korea
분석 기사 • Nov 15There May Be Underlying Issues With The Quality Of AminologicsLtd's (KOSDAQ:074430) EarningsDespite announcing strong earnings, Aminologics Co.,Ltd.'s ( KOSDAQ:074430 ) stock was sluggish. We think that the...
Reported Earnings • Nov 12Third quarter 2024 earnings released: ₩17.00 loss per share (vs ₩6.00 loss in 3Q 2023)Third quarter 2024 results: ₩17.00 loss per share (further deteriorated from ₩6.00 loss in 3Q 2023). Revenue: ₩2.39b (down 43% from 3Q 2023). Net loss: ₩1.53b (loss widened 177% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has only fallen by 24% per year, which means it has not declined as severely as earnings.
New Risk • Sep 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩102.1b market cap, or US$77.6m).
분석 기사 • Aug 13AminologicsLtd (KOSDAQ:074430) May Have Issues Allocating Its CapitalTo avoid investing in a business that's in decline, there's a few financial metrics that can provide early indications...
Valuation Update With 7 Day Price Move • Aug 05Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩1,157, the stock trades at a trailing P/E ratio of 39.5x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total loss to shareholders of 61% over the past three years.
분석 기사 • Mar 27AminologicsLtd's (KOSDAQ:074430) Shareholders May Want To Dig Deeper Than Statutory ProfitFollowing the solid earnings report from Aminologics Co.,Ltd. ( KOSDAQ:074430 ), the market responded by bidding up the...
Reported Earnings • Mar 26Full year 2023 earnings released: EPS: ₩28.00 (vs ₩83.00 loss in FY 2022)Full year 2023 results: EPS: ₩28.00 (up from ₩83.00 loss in FY 2022). Revenue: ₩20.9b (down 24% from FY 2022). Net income: ₩2.44b (up ₩9.72b from FY 2022). Profit margin: 12% (up from net loss in FY 2022). The move to profitability was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 63 percentage points per year, which is a significant difference in performance.
분석 기사 • Mar 01Some Investors May Be Worried About AminologicsLtd's (KOSDAQ:074430) Returns On CapitalWhen it comes to investing, there are some useful financial metrics that can warn us when a business is potentially in...
New Risk • Jul 26New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩123.4b (US$96.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 17% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩123.4b market cap, or US$96.4m).
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Jun 23Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to ₩2,465, the stock trades at a trailing P/E ratio of 28.1x. Average trailing P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 14% over the past three years.
Valuation Update With 7 Day Price Move • Jun 09Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₩2,845, the stock trades at a trailing P/E ratio of 32.4x. Average trailing P/E is 15x in the Chemicals industry in South Korea. Total returns to shareholders of 35% over the past three years.
Valuation Update With 7 Day Price Move • May 18Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₩2,645, the stock trades at a trailing P/E ratio of 43.3x. Average trailing P/E is 15x in the Chemicals industry in South Korea. Total returns to shareholders of 31% over the past three years.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Apr 19Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩2,310, the stock trades at a trailing P/E ratio of 37.9x. Average trailing P/E is 16x in the Chemicals industry in South Korea. Total returns to shareholders of 5.0% over the past three years.
Reported Earnings • Nov 13Third quarter 2021 earnings released: EPS ₩11.00 (vs ₩8.00 in 3Q 2020)The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2021 results: Revenue: ₩4.41b (down 15% from 3Q 2020). Net income: ₩961.5m (up 35% from 3Q 2020). Profit margin: 22% (up from 14% in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • Oct 06Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩2,345, the stock trades at a trailing P/E ratio of 29.1x. Average trailing P/E is 19x in the Chemicals industry in South Korea. Total returns to shareholders of 8.1% over the past three years.
Reported Earnings • May 19First quarter 2021 earnings released: EPS ₩10.00 (vs ₩5.00 loss in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: ₩4.41b (up 8.5% from 1Q 2020). Net income: ₩869.4m (up ₩1.30b from 1Q 2020). Profit margin: 20% (up from net loss in 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has increased by 19% per year, which means it is well ahead of earnings.
분석 기사 • May 05Returns At AminologicsLtd (KOSDAQ:074430) Are On The Way UpFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
분석 기사 • Mar 19Should Weakness in Aminologics Co.,Ltd.'s (KOSDAQ:074430) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?With its stock down 7.9% over the past three months, it is easy to disregard AminologicsLtd (KOSDAQ:074430). But if you...
Reported Earnings • Mar 19Full year 2020 earnings released: EPS ₩24.00 (vs ₩14.00 loss in FY 2019)The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2020 results: Revenue: ₩17.7b (down 7.0% from FY 2019). Net income: ₩2.14b (up ₩3.34b from FY 2019). Profit margin: 12% (up from net loss in FY 2019). Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings.
Is New 90 Day High Low • Mar 09New 90-day low: ₩2,400The company is down 19% from its price of ₩2,970 on 09 December 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 12% over the same period.
분석 기사 • Feb 04If You Had Bought AminologicsLtd (KOSDAQ:074430) Stock Five Years Ago, You Could Pocket A 137% Gain TodayWhen you buy a stock there is always a possibility that it could drop 100%. But when you pick a company that is really...
Is New 90 Day High Low • Jan 06New 90-day high: ₩3,405The company is up 49% from its price of ₩2,285 on 08 October 2020. The South Korean market is up 24% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 25% over the same period.
Is New 90 Day High Low • Dec 04New 90-day high: ₩2,740The company is up 13% from its price of ₩2,415 on 04 September 2020. The South Korean market is also up 13% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Chemicals industry, which is up 12% over the same period.
Is New 90 Day High Low • Oct 18New 90-day low: ₩2,030The company is down 2.0% from its price of ₩2,080 on 20 July 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 25% over the same period.
